Oligonucleotides News and Research RSS Feed - Oligonucleotides News and Research

Oligonucleotides are short sequences of nucleotides (RNA or DNA), typically with twenty or fewer bases. Automated synthesizers allow the synthesis of oligonucleotides up to 160 to 200 bases.
New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

New mouse study indicates that mutant protein in muscle cells is responsible for SBMA

Sometimes known as Kennedy's disease, spinal and bulbar muscular atrophy (SBMA) is a rare inherited neuromuscular disorder characterized by slowly progressive muscle weakness and atrophy. [More]
miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

miRNA expression and inhibition: an interview with Maja Petkovic, AMSBIO

RNA interference is a process in which RNA molecules inhibit gene expression. This gene silencing process is controlled by RNA-induced silencing complex or RISC and is initiated by small duplex RNA molecules or miRNA that is present inside cell plasma. [More]
Concise analysis of cancer drug delivery markets

Concise analysis of cancer drug delivery markets

Research and Markets (http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report "Drug Delivery in Cancer - Technologies, Markets and Companies" to their offering. [More]
Blood sample could diagnose many types of solid cancers

Blood sample could diagnose many types of solid cancers

A blood sample could one day be enough to diagnose many types of solid cancers, or to monitor the amount of cancer in a patient's body and responses to treatment. Previous versions of the approach, which relies on monitoring levels of tumor DNA circulating in the blood, have required cumbersome and time-consuming steps to customize it to each patient or have not been sufficiently sensitive. [More]
ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

ANP reports positive results from chronic toxicity study of ATL1102 in multiple sclerosis

Antisense Therapeutics Limited is pleased to advise that results from a chronic toxicity study in monkeys indicate that ATL1102, an antisense oligonucleotide currently under development for the treatment of multiple sclerosis (MS), was well-tolerated when given subcutaneously for a 6-month dosing period at the 2 dose levels tested (1.5 and 3mg/kg/dose). [More]
Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals reports positive top-line results from Phase 2 trial of IMO-8400

Idera Pharmaceuticals, Inc. today announced positive top-line data from its randomized, double-blind, placebo controlled Phase 2 trial of IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis. [More]
Chemical engineers design way to manufacture peptides in mere hours

Chemical engineers design way to manufacture peptides in mere hours

Small protein fragments, also called peptides, are promising as drugs because they can be designed for very specific functions inside living cells. Insulin and the HIV drug Fuzeon are some of the earliest successful examples, and peptide drugs are expected to become a $25 billion market by 2018. [More]

OPKO Health consolidated revenues increase about 30% to $20.7 million in Q4 2013

OPKO Health, Inc., a multi-national biopharmaceutical and diagnostics company, today reported operating and financial results for its 2013 fourth quarter and full year ended December 31, 2013. [More]
New approach for reducing levels of toxic protein fragments associated with Huntington's disease

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin. [More]

Scientists develop new approach to design drugs from genome sequence

In research that could ultimately lead to many new medicines, scientists from the Florida campus of The Scripps Research Institute (TSRI) have developed a potentially general approach to design drugs from genome sequence. As a proof of principle, they identified a highly potent compound that causes cancer cells to attack themselves and die. [More]
Ready-to-use human and mouse lentivirus products for miRNA expression and inhibition introduced by AMSBIO

Ready-to-use human and mouse lentivirus products for miRNA expression and inhibition introduced by AMSBIO

... [More]
Chinese and American researchers introduce new approach to gene therapy

Chinese and American researchers introduce new approach to gene therapy

Resistance of tumor cells toward multiple cytostatic drugs is a serious problem in cancer treatment. In the journal Angewandte Chemie, a team of Chinese and American researchers has now introduced a new approach to gene therapy that could counter this problem: The gene that codes for resistance is “silenced” through the use of an ingenious nanocomplex. [More]

Genevac provides new tool for drying DNA and oligonucleotide samples

A technical article is available from Genevac that describes a rapid, safe technique for drying oligonucleotide and DNA samples. [More]

Aptamer kits for cell isolation and flow cytometry introduced by AMSBIO

AMSBIO has announced the introduction of new aptamer kits for cell isolation and flow cytometry. Aptamers are oligonucleotides or peptides that bind to a specific target molecule. Aptamers are useful in biotechnological and therapeutic applications as they offer molecular recognition properties that rival that of the commonly used biomolecule, antibodies. [More]
New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

New technology efficiently transfers investigational antibodies from blood via blood-brain barrier

Today the scientific journal Neuron published results on the Roche-designed Brain Shuttle technology that efficiently transfers investigational antibodies from the blood through the blood-brain barrier (BBB) into the brain in preclinical models. [More]

FDA grants orphan drug designation for DiaVacs' type 1 diabetes mellitus therapy

DiaVacs, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for the company's type 1 diabetes mellitus (T1DM) therapy. [More]
Market research report on PCSK9 inhibitors

Market research report on PCSK9 inhibitors

Research and Markets has announced the addition of the "PCSK9 Inhibitors - The hot new approach to lower cholesterol" report to their offering. [More]
Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

Mouse study highlights importance of microorganisms in optimal cancer treatment outcomes

... [More]
Study uncovers novel mechanism that helps govern regulated gene expression

Study uncovers novel mechanism that helps govern regulated gene expression

A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology. [More]

Agilent collaborates with Baylor College of Medicine to provide CGH microarrays to researchers

Agilent Technologies Inc. has announced it is collaborating with Baylor College of Medicine's Medical Genetics Laboratories to provide customized CGH (comparative genomics hybridization) microarrays to researchers worldwide. Six new microarray designs unite the power of Baylor's data-rich expertise in genetics research with Agilent's microarray manufacturing capabilities to enable advanced discoveries in cancer and cytogenetics research. [More]